Aligos Therapeutics reported net income of -$1.50M for the quarter ended Jun 2026. This income statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||||
| Revenue | 1.54M | 0.37M | 2.57M | 3.69M | 4.11M | 3.54M | 2.58M | 4.29M | 2.15M | 2.01M | 0.69M | 1.06M | 1.25M | 0.61M | 0.31M | 0.97M | 0.74M | 0.17M | 2.83M | |||||||||
| Operating items | ||||||||||||||||||||||||||||
| Research & DevelopmentR&D | 28.13M | 28.60M | 31.68M | 16.51M | 17.79M | 19.10M | 18.14M | 16.78M | 15.87M | 22.26M | 16.37M | 21.10M | 16.77M | 16.03M | 14.50M | 13.98M | 23.94M | 17.04M | 23.35M | 24.05M | ||||||||
| Selling, General & AdministrativeSG&A | 6.47M | 9.72M | 6.45M | 7.58M | 5.26M | 7.12M | 8.51M | 9.25M | 6.44M | 6.42M | 6.67M | 6.38M | 4.63M | 5.16M | 5.05M | 5.56M | 5.17M | 4.95M | 6.41M | 5.62M | ||||||||
| Other Operating ExpensesOther Opex | 0.07M | 0.18M | -0.01M | 0.52M | 0.28M | 0.85M | 1.00M | 1.11M | 1.06M | 0.24M | 1.58M | 1.23M | 1.07M | 0.57M | 0.88M | 1.21M | 1.09M | 0.75M | 0.81M | 0.22M | ||||||||
| Operating ExpensesOpex | 34.61M | 38.32M | 38.13M | 24.09M | 23.05M | 26.22M | 26.64M | 26.03M | 22.31M | 28.68M | 23.03M | 27.48M | 21.40M | 21.19M | 19.55M | 19.53M | 29.10M | 21.98M | 29.76M | 29.67M | ||||||||
| Operating IncomeOp. Inc | -33.07M | -37.95M | -35.56M | -20.39M | -18.95M | -22.68M | -23.92M | -19.14M | -19.07M | -26.00M | -22.05M | -26.41M | -20.13M | -20.56M | -19.24M | -18.57M | -28.36M | -21.81M | -26.93M | -1.89M | ||||||||
| EBIT | -33.07M | -37.95M | -35.56M | -20.39M | -18.95M | -22.68M | -23.92M | -19.14M | -19.07M | -26.00M | -22.05M | -26.41M | -20.13M | -20.56M | -19.24M | -18.57M | -28.36M | -21.81M | -26.93M | -1.89M | ||||||||
| Net income details | ||||||||||||||||||||||||||||
| EBT | -33.00M | -37.77M | -35.56M | -19.88M | -18.66M | -21.84M | -22.92M | -18.03M | -18.01M | -27.92M | -34.84M | 5.25M | -19.17M | -82.12M | 43.13M | -15.68M | -31.48M | -19.85M | -22.72M | 1.31M | ||||||||
| Tax ProvisionsTaxes | 0.13M | -0.06M | 0.05M | 0.05M | -0.04M | 0.05M | 0.04M | 0.76M | 0.03M | -0.03M | 0.02M | 0.19M | 0.09M | 0.03M | 0.04M | 0.19M | 0.06M | 0.03M | 0.32M | 2.81M | ||||||||
| Profit After TaxPAT | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.96M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -19.88M | -23.04M | -1.50M | ||||||||
| Income from Continuing OperationsIncome (Continuing) | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.96M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -19.88M | -23.04M | -1.50M | ||||||||
| Consolidated Net IncomeConsol Net Inc. | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.96M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -19.88M | -23.04M | -1.50M | ||||||||
| Income towards Parent CompanyParent Net Inc | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.96M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -19.88M | -23.04M | -1.50M | ||||||||
| Net Income towards Common StockholdersNet Income | -33.12M | -37.71M | -35.62M | -19.92M | -18.62M | -21.89M | -22.96M | -18.79M | -18.04M | -27.89M | -34.86M | 5.06M | -19.26M | -82.15M | 43.09M | -15.86M | -31.54M | -19.88M | -23.04M | -1.50M | ||||||||
| Additional items | ||||||||||||||||||||||||||||
| EPS (Basic) | -0.78 | -0.95 | -0.84 | -0.47 | -0.44 | -0.51 | -0.53 | -0.43 | -0.41 | -0.43 | -0.22 | 0.03 | -3.07 | -13.11 | 5.12 | -1.53 | -3.04 | -2.01 | -2.21 | -0.14 | ||||||||
| EPS (Diluted) | -0.78 | -0.89 | -0.84 | -0.47 | -0.44 | -0.51 | -0.53 | -0.43 | -0.41 | -0.43 | -0.22 | 0.03 | -3.07 | -13.11 | 4.95 | -1.53 | -3.04 | -2.01 | -2.21 | -0.14 | ||||||||
| Shares Outstanding | 42.40M | 39.86M | 42.51M | 42.67M | 42.76M | 42.70M | 42.91M | 43.22M | 43.50M | 64.26M | 156.15M | 156.44M | 6.27M | 6.26M | 8.41M | 10.35M | 10.37M | 9.88M | 10.40M | 10.43M | ||||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 42.40M | 42.40M | 42.51M | 42.67M | 42.76M | 42.70M | 42.91M | 43.22M | 43.50M | 64.26M | 156.15M | 156.65M | 6.27M | 6.26M | 8.71M | 10.35M | 10.37M | 9.88M | 10.40M | 10.43M | ||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 42.61M | 42.69M | 42.70M | 42.81M | 42.82M | 42.92M | 42.94M | 43.50M | 43.50M | 64.26M | 156.15M | 156.44M | 6.27M | 6.26M | 8.41M | 10.35M | 10.37M | 9.88M | 10.40M | 10.43M | ||||||||
| EBITDA | -32.27M | -37.23M | -34.86M | -19.79M | -18.45M | -22.18M | -23.42M | -18.74M | -18.77M | -25.60M | -21.75M | -26.11M | -19.83M | -20.34M | -19.04M | -18.27M | -28.16M | -21.58M | -26.58M | -1.59M | ||||||||
| Tax Rate | 3.60% | 0.10% | 215.07% |
Pull Aligos Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ALGS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ALGS", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ALGS&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();